60 Degrees Pharmaceuticals reported Q3 2024 product revenues of $135,293, up 164% YoY, driven by strong growth in Arakoda sales. The company achieved a gross profit of $23,606 compared to a loss of $20,008 in Q3 2023, with gross margin improving to 17.45%. U.S. pharmaceutical distributor accounted for 92% of total net product sales, while Kodatef sales to Australian distributor represented 8%.Research and development expenses increased to $940,063 from $263,703 YoY, primarily due to $600,000 in research material costs and $270,497 in babesiosis trial expenses. General and administrative expenses decreased 7.5% to $1.2 million, despite higher compensation and operational costs, offset by lower stock-based compensation.The company ended the quarter with $3.3 million in cash, bolstered by net proceeds of $1.8 million from ATM offerings and $3.4 million from a private placement. Management estimates sufficient funds through June 2025, excluding planned babesiosis study costs. The company continues to focus on increasing Arakoda sales and advancing clinical trials for new indications.

60 Degrees Pharmaceuticals reported Q3 2024 product revenues of $135,293, up 164% YoY, driven by strong growth in Arakoda sales. The company achieved a gross profit of $23,606 compared to a loss of $20,008 in Q3 2023, with gross margin improving to 17.45%. U.S. pharmaceutical distributor accounted for 92% of total net product sales, while Kodatef sales to Australian distributor represented 8%.Research and development expenses increased to $940,063 from $263,703 YoY, primarily due to $600,000 in research material costs and $270,497 in babesiosis trial expenses. General and administrative expenses decreased 7.5% to $1.2 million, despite higher compensation and operational costs, offset by lower stock-based compensation.The company ended the quarter with $3.3 million in cash, bolstered by net proceeds of $1.8 million from ATM offerings and $3.4 million from a private placement. Management estimates sufficient funds through June 2025, excluding planned babesiosis study costs. The company continues to focus on increasing Arakoda sales and advancing clinical trials for new indications.